714 related articles for article (PubMed ID: 19285528)
1. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
Abu Lila AS; Kizuki S; Doi Y; Suzuki T; Ishida T; Kiwada H
J Control Release; 2009 Jul; 137(1):8-14. PubMed ID: 19285528
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.
Abu-Lila A; Suzuki T; Doi Y; Ishida T; Kiwada H
J Control Release; 2009 Feb; 134(1):18-25. PubMed ID: 19010364
[TBL] [Abstract][Full Text] [Related]
3. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor.
Abu Lila AS; Doi Y; Nakamura K; Ishida T; Kiwada H
J Control Release; 2010 Mar; 142(2):167-73. PubMed ID: 19861140
[TBL] [Abstract][Full Text] [Related]
4. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.
Abu Lila AS; Eldin NE; Ichihara M; Ishida T; Kiwada H
Int J Pharm; 2012 Nov; 438(1-2):176-83. PubMed ID: 22944302
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism?
Abu Lila AS; Okada T; Doi Y; Ichihara M; Ishida T; Kiwada H
Int J Pharm; 2012 Apr; 426(1-2):263-270. PubMed ID: 22310465
[TBL] [Abstract][Full Text] [Related]
6. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome.
Suzuki R; Takizawa T; Kuwata Y; Mutoh M; Ishiguro N; Utoguchi N; Shinohara A; Eriguchi M; Yanagie H; Maruyama K
Int J Pharm; 2008 Jan; 346(1-2):143-50. PubMed ID: 17640835
[TBL] [Abstract][Full Text] [Related]
7. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.
Abu Lila AS; Matsumoto H; Doi Y; Nakamura H; Ishida T; Kiwada H
Eur J Pharm Biopharm; 2012 Aug; 81(3):524-31. PubMed ID: 22554766
[TBL] [Abstract][Full Text] [Related]
8. PEG-liposomal oxaliplatin potentialization of antitumor efficiency in a nude mouse tumor-xenograft model of colorectal carcinoma.
Yang C; Liu HZ; Lu WD; Fu ZX
Oncol Rep; 2011 Jun; 25(6):1621-8. PubMed ID: 21455585
[TBL] [Abstract][Full Text] [Related]
9. Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery.
Tagami T; Suzuki T; Matsunaga M; Nakamura K; Moriyoshi N; Ishida T; Kiwada H
Int J Pharm; 2012 Jan; 422(1-2):280-9. PubMed ID: 22101286
[TBL] [Abstract][Full Text] [Related]
10. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome.
Maeda N; Takeuchi Y; Takada M; Sadzuka Y; Namba Y; Oku N
J Control Release; 2004 Nov; 100(1):41-52. PubMed ID: 15491809
[TBL] [Abstract][Full Text] [Related]
11. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
12. Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes.
Katanasaka Y; Ida T; Asai T; Maeda N; Oku N
Int J Pharm; 2008 Aug; 360(1-2):219-24. PubMed ID: 18565703
[TBL] [Abstract][Full Text] [Related]
13. Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo.
Lee CM; Tanaka T; Murai T; Kondo M; Kimura J; Su W; Kitagawa T; Ito T; Matsuda H; Miyasaka M
Cancer Res; 2002 Aug; 62(15):4282-8. PubMed ID: 12154030
[TBL] [Abstract][Full Text] [Related]
14. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
15. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol).
Parr MJ; Masin D; Cullis PR; Bally MB
J Pharmacol Exp Ther; 1997 Mar; 280(3):1319-27. PubMed ID: 9067319
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model.
Doi Y; Okada T; Matsumoto H; Ichihara M; Ishida T; Kiwada H
Cancer Sci; 2010 Nov; 101(11):2470-5. PubMed ID: 20731663
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in tumor vasculature targeting using liposomal drug delivery systems.
Abu Lila AS; Ishida T; Kiwada H
Expert Opin Drug Deliv; 2009 Dec; 6(12):1297-309. PubMed ID: 19780711
[TBL] [Abstract][Full Text] [Related]
19. Effective tumor regression by anti-neovascular therapy in hypovascular orthotopic pancreatic tumor model.
Yonezawa S; Asai T; Oku N
J Control Release; 2007 Apr; 118(3):303-9. PubMed ID: 17275944
[TBL] [Abstract][Full Text] [Related]
20. Polyethylene glycol-complexed cationic liposome for enhanced cellular uptake and anticancer activity.
Jung SH; Jung SH; Seong H; Cho SH; Jeong KS; Shin BC
Int J Pharm; 2009 Dec; 382(1-2):254-61. PubMed ID: 19666094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]